Selected research
Industry Research
Ovulation Stimulants Industry Research Report 2026
Market perspective
The global Ovulation Stimulants market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Ovulation Stimulants is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Ovulation Stimulants is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Ovulation Stimulants is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Ovulation Stimulants include Takeda, Merck & Co. Inc, AbbVie, AstraZeneca, TerSera Therapeutics, Techwell, Sun Pharmaceutical, LIVZON and Ipsen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Ovulation Stimulants market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Ovulation Stimulants Market by Company
Takeda
Merck & Co. Inc
AbbVie
AstraZeneca
TerSera Therapeutics
Techwell
Sun Pharmaceutical
LIVZON
Ipsen
IBSA
Gedeon Richter
Fresenius Kabi
Ferring
Endo
Bristol Myers Squibb
Ovulation Stimulants Segment by Type
Luteinizing Hormone (LH)
Follicle-Stimulating Hormone (FSH)
Human Chorionic Gonadotropin (HCG)
Ovulation Stimulants Segment by Application
Clinic
Hospital
Medical Institution
Ovulation Stimulants Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ovulation Stimulants market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Ovulation Stimulants and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ovulation Stimulants.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Ovulation Stimulants manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Ovulation Stimulants by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Ovulation Stimulants in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Luteinizing Hormone (LH)
- Follicle-Stimulating Hormone (FSH)
- Human Chorionic Gonadotropin (HCG)
Applications
- Clinic
- Hospital
- Medical Institution
Companies covered
- Takeda
- Merck & Co. Inc
- AbbVie
- AstraZeneca
- TerSera Therapeutics
- Techwell
- Sun Pharmaceutical
- LIVZON
- Ipsen
- IBSA
- Gedeon Richter
- Fresenius Kabi
- Ferring
- Endo
- Bristol Myers Squibb
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Ovulation Stimulants Market Size (2021-2032)
- 2.2.2 Global Ovulation Stimulants Sales (2021-2032)
- 2.2.3 Global Ovulation Stimulants Market Average Price (2021-2032)
- 2.3 Ovulation Stimulants by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Luteinizing Hormone (LH)
- 2.3.3 Follicle-Stimulating Hormone (FSH)
- 2.3.4 Human Chorionic Gonadotropin (HCG)
- 2.4 Ovulation Stimulants by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Clinic
- 2.4.3 Hospital
- 2.4.4 Medical Institution
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Ovulation Stimulants Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Ovulation Stimulants Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Ovulation Stimulants Revenue of Manufacturers (2021-2026)
- 3.4 Global Ovulation Stimulants Average Price by Manufacturers (2021-2026)
- 3.5 Global Ovulation Stimulants Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Ovulation Stimulants, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Ovulation Stimulants, Product Type & Application
- 3.8 Global Manufacturers of Ovulation Stimulants, Established Date
- 3.9 Global Ovulation Stimulants Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda
- 4.1.1 Takeda Company Information
- 4.1.2 Takeda Business Overview
- 4.1.3 Takeda Ovulation Stimulants Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Ovulation Stimulants Product Portfolio
- 4.1.5 Takeda Recent Developments
- 4.2 Merck & Co. Inc
- 4.2.1 Merck & Co. Inc Company Information
- 4.2.2 Merck & Co. Inc Business Overview
- 4.2.3 Merck & Co. Inc Ovulation Stimulants Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck & Co. Inc Ovulation Stimulants Product Portfolio
- 4.2.5 Merck & Co. Inc Recent Developments
- 4.3 AbbVie
- 4.3.1 AbbVie Company Information
- 4.3.2 AbbVie Business Overview
- 4.3.3 AbbVie Ovulation Stimulants Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 AbbVie Ovulation Stimulants Product Portfolio
- 4.3.5 AbbVie Recent Developments
- 4.4 AstraZeneca
- 4.4.1 AstraZeneca Company Information
- 4.4.2 AstraZeneca Business Overview
- 4.4.3 AstraZeneca Ovulation Stimulants Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 AstraZeneca Ovulation Stimulants Product Portfolio
- 4.4.5 AstraZeneca Recent Developments
- 4.5 TerSera Therapeutics
- 4.5.1 TerSera Therapeutics Company Information
- 4.5.2 TerSera Therapeutics Business Overview
- 4.5.3 TerSera Therapeutics Ovulation Stimulants Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 TerSera Therapeutics Ovulation Stimulants Product Portfolio
- 4.5.5 TerSera Therapeutics Recent Developments
- 4.6 Techwell
- 4.6.1 Techwell Company Information
- 4.6.2 Techwell Business Overview
- 4.6.3 Techwell Ovulation Stimulants Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Techwell Ovulation Stimulants Product Portfolio
- 4.6.5 Techwell Recent Developments
- 4.7 Sun Pharmaceutical
- 4.7.1 Sun Pharmaceutical Company Information
- 4.7.2 Sun Pharmaceutical Business Overview
- 4.7.3 Sun Pharmaceutical Ovulation Stimulants Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Sun Pharmaceutical Ovulation Stimulants Product Portfolio
- 4.7.5 Sun Pharmaceutical Recent Developments
- 4.8 LIVZON
- 4.8.1 LIVZON Company Information
- 4.8.2 LIVZON Business Overview
- 4.8.3 LIVZON Ovulation Stimulants Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 LIVZON Ovulation Stimulants Product Portfolio
- 4.8.5 LIVZON Recent Developments
- 4.9 Ipsen
- 4.9.1 Ipsen Company Information
- 4.9.2 Ipsen Business Overview
- 4.9.3 Ipsen Ovulation Stimulants Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Ipsen Ovulation Stimulants Product Portfolio
- 4.9.5 Ipsen Recent Developments
- 4.10 IBSA
- 4.10.1 IBSA Company Information
- 4.10.2 IBSA Business Overview
- 4.10.3 IBSA Ovulation Stimulants Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 IBSA Ovulation Stimulants Product Portfolio
- 4.10.5 IBSA Recent Developments
- 4.11 Gedeon Richter
- 4.11.1 Gedeon Richter Company Information
- 4.11.2 Gedeon Richter Business Overview
- 4.11.3 Gedeon Richter Ovulation Stimulants Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Gedeon Richter Ovulation Stimulants Product Portfolio
- 4.11.5 Gedeon Richter Recent Developments
- 4.12 Fresenius Kabi
- 4.12.1 Fresenius Kabi Company Information
- 4.12.2 Fresenius Kabi Business Overview
- 4.12.3 Fresenius Kabi Ovulation Stimulants Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Fresenius Kabi Ovulation Stimulants Product Portfolio
- 4.12.5 Fresenius Kabi Recent Developments
- 4.13 Ferring
- 4.13.1 Ferring Company Information
- 4.13.2 Ferring Business Overview
- 4.13.3 Ferring Ovulation Stimulants Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Ferring Ovulation Stimulants Product Portfolio
- 4.13.5 Ferring Recent Developments
- 4.14 Endo
- 4.14.1 Endo Company Information
- 4.14.2 Endo Business Overview
- 4.14.3 Endo Ovulation Stimulants Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Endo Ovulation Stimulants Product Portfolio
- 4.14.5 Endo Recent Developments
- 4.15 Bristol Myers Squibb
- 4.15.1 Bristol Myers Squibb Company Information
- 4.15.2 Bristol Myers Squibb Business Overview
- 4.15.3 Bristol Myers Squibb Ovulation Stimulants Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Bristol Myers Squibb Ovulation Stimulants Product Portfolio
- 4.15.5 Bristol Myers Squibb Recent Developments
5 Global Ovulation Stimulants Market Scenario by Region
- 5.1 Global Ovulation Stimulants Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Ovulation Stimulants Sales by Region: 2021-2032
- 5.2.1 Global Ovulation Stimulants Sales by Region: 2021-2026
- 5.2.2 Global Ovulation Stimulants Sales by Region: 2027-2032
- 5.3 Global Ovulation Stimulants Revenue by Region: 2021-2032
- 5.3.1 Global Ovulation Stimulants Revenue by Region: 2021-2026
- 5.3.2 Global Ovulation Stimulants Revenue by Region: 2027-2032
- 5.4 North America Ovulation Stimulants Market Facts & Figures by Country
- 5.4.1 North America Ovulation Stimulants Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Ovulation Stimulants Sales by Country (2021-2032)
- 5.4.3 North America Ovulation Stimulants Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Ovulation Stimulants Market Facts & Figures by Country
- 5.5.1 Europe Ovulation Stimulants Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Ovulation Stimulants Sales by Country (2021-2032)
- 5.5.3 Europe Ovulation Stimulants Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Ovulation Stimulants Market Facts & Figures by Country
- 5.6.1 Asia Pacific Ovulation Stimulants Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Ovulation Stimulants Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Ovulation Stimulants Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Ovulation Stimulants Market Facts & Figures by Country
- 5.7.1 South America Ovulation Stimulants Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Ovulation Stimulants Sales by Country (2021-2032)
- 5.7.3 South America Ovulation Stimulants Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Ovulation Stimulants Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Ovulation Stimulants Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Ovulation Stimulants Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Ovulation Stimulants Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Ovulation Stimulants Sales by Type (2021-2032)
- 6.1.1 Global Ovulation Stimulants Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Ovulation Stimulants Sales Market Share by Type (2021-2032)
- 6.2 Global Ovulation Stimulants Revenue by Type (2021-2032)
- 6.2.1 Global Ovulation Stimulants Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Ovulation Stimulants Revenue Market Share by Type (2021-2032)
- 6.3 Global Ovulation Stimulants Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Ovulation Stimulants Sales by Application (2021-2032)
- 7.1.1 Global Ovulation Stimulants Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Ovulation Stimulants Sales Market Share by Application (2021-2032)
- 7.2 Global Ovulation Stimulants Revenue by Application (2021-2032)
- 7.2.1 Global Ovulation Stimulants Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Ovulation Stimulants Revenue Market Share by Application (2021-2032)
- 7.3 Global Ovulation Stimulants Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Ovulation Stimulants Value Chain Analysis
- 8.1.1 Ovulation Stimulants Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Ovulation Stimulants Production Mode & Process
- 8.2 Ovulation Stimulants Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Ovulation Stimulants Distributors
- 8.2.3 Ovulation Stimulants Customers
9 Global Ovulation Stimulants Analyzing Market Dynamics
- 9.1 Ovulation Stimulants Industry Trends
- 9.2 Ovulation Stimulants Industry Drivers
- 9.3 Ovulation Stimulants Industry Opportunities and Challenges
- 9.4 Ovulation Stimulants Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst